Page last updated: 2024-12-07

melezitose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Melezitose is a trisaccharide composed of glucose, fructose, and glucose. It is found in the honeydew of certain insects, particularly aphids and scale insects, and in the sap of some plants. Melezitose is highly soluble in water and has a sweet taste. It is not easily metabolized by humans and can cause digestive discomfort. It has been studied for its potential to be used as a prebiotic, a substance that promotes the growth of beneficial bacteria in the gut. Melezitose has also been investigated for its potential to inhibit the growth of certain types of bacteria and fungi. It is also being studied for its potential to improve the storage stability of food products.'

melezitose: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

melezitose : A trisaccharide produced by insects such as aphids. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID92817
CHEMBL ID386007
CHEBI ID6731
SCHEMBL ID131977
MeSH IDM0046554

Synonyms (43)

Synonym
alpha-d-glucopyranosyl-(1->3)-beta-d-fructofuranosyl alpha-d-glucopyranoside
CHEBI:6731 ,
melizitose
o-alpha-d-glucopyranosyl-(1-3)-beta-d-fructofuranosyl-alpha-d-glucopyranoside
d-(+)-melezitose
(2r,3r,4s,5s,6r)-2-[(2s,3s,4r,5r)-4-hydroxy-2,5-bis(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-tetrahydrofuran-3-yl]oxy-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol
.alpha.-d-glucopyranoside, o-.alpha.-d-glucopyranosyl-(1-3)-.beta.-d-fructofuranosyl-
597-12-6
C08243
melezitose
58079E13-F3CD-4185-B028-4BD36A97D4D3
CHEMBL386007
M0049
o-alpha-d-glucopyranosyl-(1,3)-beta-d-fructofuranosyl-alpha-d-glucopyranoside
AKOS015955765
einecs 209-894-9
unii-t4t25qn29l
t4t25qn29l ,
ai3-19426
alpha-d-glucopyranoside, o-alpha-d-glucopyranosyl-(1.fwdarw.3)-beta-d-fructofuranosyl
alpha-d-glucopyranoside, o-alpha-d-glucopyranosyl-(1->3)-beta-d-fructofuranosyl
(2r,3r,4s,5s,6r)-2-{[(2s,3s,4r,5r)-4-hydroxy-2,5-bis(hydroxymethyl)-2-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxolan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
melicitose
S5142
SCHEMBL131977
.alpha.-d-glucopyranoside, o-.alpha.-d-glucopyranosyl-(1->3)-.beta.-d-fructofuranosyl
o-.alpha.-d-glucopyranosyl-(1->3)-.beta.-d-fructofuranosyl-.alpha.-d-glucopyranoside
(+)-melezitose
melezitose [mi]
melezitose, (+)-
wurcs=2.0/2,3,2/[a2122h-1a_1-5][ha122h-2b_2-5]/1-2-1/a1-b2_b3-c1
melezitose (6ci,8ci); o-?-d-glucopyranosyl-(1?3)-?-d-fructofuranosyl ?-d-glucopyranoside; (+)-melezitose; d-(+)-melezitose; d-melezitose
d(+)-melezitose 1-hydrate
HY-N2340
CS-6328
(2r,3r,4s,5s,6r)-2-[(2s,3s,4r,5r)-4-hydroxy-2,5-bis(hydroxymethyl)-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DTXSID20883458
Q418842
(2r,2'r,3s,3's,4s,4's,5r,5'r,6r,6'r)-6,6'-((2s,3s,4r,5r)-4-hydroxy-2,5-bis(hydroxymethyl)tetrahydrofuran-2,3-diyl)bis(oxy)bis(2-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol)
CCG-269726
C75789
AS-56726
d-(+)melezitose

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" When mixed B and T lymphocyte populations were stimulated by LB a bell-shaped dose-response curve resulted which is also characteristic of the corresponding lectins; LB, however, act at much higher concentrations than the lectins."( Lectin-binding proteins as potent mitogens for B lymphocytes from nu/nu mice.
Gebauer, G; RĂ¼diger, H; Schimpl, A, 1982
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
animal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in animals that include diverse creatures from sponges, insects to mammals.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
trisaccharide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID276656Antihyperlipidemic activity measured by decrease in free fatty acid level in golden syrian hamster at 100 mg/kg, po relative to control2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Synthesis and antihyperlipidemic activity of novel glycosyl fructose derivatives.
AID276654Antihyperlipidemic activity measured by decrease in glycerol level in golden syrian hamster at 100 mg/kg, po relative to control2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Synthesis and antihyperlipidemic activity of novel glycosyl fructose derivatives.
AID276673Antihyperlipidemic activity measured by HDL/total cholesterol ratio in golden syrian hamster at 100 mg/kg, po2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Synthesis and antihyperlipidemic activity of novel glycosyl fructose derivatives.
AID276653Antihyperlipidemic activity measured by increase in HDL level in golden syrian hamster at 100 mg/kg, po relative to control2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Synthesis and antihyperlipidemic activity of novel glycosyl fructose derivatives.
AID276652Antihyperlipidemic activity measured by increase in cholesterol level in golden syrian hamster at 100 mg/kg, po relative to control2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Synthesis and antihyperlipidemic activity of novel glycosyl fructose derivatives.
AID276671Antihyperlipidemic activity measured by glycerol level in golden syrian hamster at 100 mg/kg, po2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Synthesis and antihyperlipidemic activity of novel glycosyl fructose derivatives.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID276672Antihyperlipidemic activity measured by free fatty acid level in golden syrian hamster at 100 mg/kg, po2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Synthesis and antihyperlipidemic activity of novel glycosyl fructose derivatives.
AID276649Antihyperlipidemic activity measured by decrease in triglyceride level in golden syrian hamster at 100 mg/kg, po relative to control2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Synthesis and antihyperlipidemic activity of novel glycosyl fructose derivatives.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID276670Antihyperlipidemic activity measured by HDL level in golden syrian hamster at 100 mg/kg, po2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Synthesis and antihyperlipidemic activity of novel glycosyl fructose derivatives.
AID276659Antihyperlipidemic activity measured by increase in HDL/total cholesterol ratio in golden syrian hamster at 100 mg/kg, po relative to control2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Synthesis and antihyperlipidemic activity of novel glycosyl fructose derivatives.
AID276668Antihyperlipidemic activity measured by triglyceride level in golden syrian hamster at 100 mg/kg, po2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Synthesis and antihyperlipidemic activity of novel glycosyl fructose derivatives.
AID276669Antihyperlipidemic activity measured by cholesterol level in golden syrian hamster at 100 mg/kg, po2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Synthesis and antihyperlipidemic activity of novel glycosyl fructose derivatives.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (47)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (31.91)18.7374
1990's2 (4.26)18.2507
2000's12 (25.53)29.6817
2010's13 (27.66)24.3611
2020's5 (10.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.55 (24.57)
Research Supply Index3.87 (2.92)
Research Growth Index5.13 (4.65)
Search Engine Demand Index80.21 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (52.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (4.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other45 (95.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]